Literature DB >> 18004755

Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.

Weihua Li1, Yun Tang, Hong Liu, Jiagao Cheng, Weiliang Zhu, Hualiang Jiang.   

Abstract

Cytochrome P450 (P450) 2J2 catalyzes epoxidation of arachidonic acid to eicosatrienoic acids, which are related to a variety of diseases such as coronary artery disease, hypertension, and carcinogenesis. Recent experimental data also suggest that P450 2J2 could be a novel biomarker and a potential target for cancer therapy. However, the active site topology and substrate specificity of this enzyme remain unclear. In this study, a three-dimensional model of human P450 2J2 was first constructed on the basis of the crystal structure of human P450 2C9 in complex with a substrate using homology modeling method, and refined by molecular dynamics simulation. Flexible docking approaches were then employed to dock four ligands into the active site of P450 2J2 in order to probe the ligand-binding modes. By analyzing the results, active site architecture and certain key residues responsible for substrate specificity were identified on the enzyme, which might be very helpful for understanding the enzyme's biological role and providing insights for designing novel inhibitors of P450 2J2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18004755     DOI: 10.1002/prot.21778

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  13 in total

1.  Accurate prediction of the bound form of the Akt pleckstrin homology domain using normal mode analysis to explore structural flexibility.

Authors:  Hoang T Tran; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-08-25       Impact factor: 4.956

Review 2.  Cytochrome P450 2U1, a very peculiar member of the human P450s family.

Authors:  L Dhers; L Ducassou; J-L Boucher; D Mansuy
Journal:  Cell Mol Life Sci       Date:  2017-01-12       Impact factor: 9.261

Review 3.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

4.  Paenibacillus sp. strain E18 bifunctional xylanase-glucanase with a single catalytic domain.

Authors:  Pengjun Shi; Jian Tian; Tiezheng Yuan; Xin Liu; Huoqing Huang; Yingguo Bai; Peilong Yang; Xiaoyan Chen; Ningfeng Wu; Bin Yao
Journal:  Appl Environ Microbiol       Date:  2010-04-09       Impact factor: 4.792

5.  Computational modelling of the binding of arachidonic acid to the human monooxygenase CYP2J2.

Authors:  G Proietti; K K Abelak; D Bishop-Bailey; A Macchiarulo; I Nobeli
Journal:  J Mol Model       Date:  2016-10-28       Impact factor: 1.810

6.  Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation.

Authors:  Rongwei Shi; Jinyu Li; Xiaoning Cao; Xiaolei Zhu; Xiaohua Lu
Journal:  J Mol Model       Date:  2010-12-01       Impact factor: 1.810

7.  Comparative analysis of binding affinities between styrene and mammalian CYP2E1 by bioinformatics approaches.

Authors:  Bing Wu; Jie Sun; Shu-Pei Cheng; Ji-Dong Gu; Ai-Min Li; Xu-Xiang Zhang
Journal:  Ecotoxicology       Date:  2011-03-22       Impact factor: 2.823

8.  Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods.

Authors:  Rui-Juan Niu; Qing-Chuan Zheng; Ji-Long Zhang; Hong-Xing Zhang
Journal:  J Mol Model       Date:  2011-02-08       Impact factor: 1.810

9.  Computational insights into the binding modes of Sr-Rex with cofactor NADH/NAD+ and operator DNA.

Authors:  Yanyan Chu; Weihua Li; Jianfeng Wang; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2013-04-25       Impact factor: 1.810

10.  Molecular cloning, expression and molecular modeling of chemosensory protein from Spodoptera litura and its binding properties with Rhodojaponin III.

Authors:  Yanbo Zhang; Xiaolin Dong; Jinxiang Liu; Meiying Hu; Guohua Zhong; Peng Geng; Xin Yi
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.